On 15 October 2026, Takeda announced that ORZEYFUL (oveporexton) is now available in Japan and China for narcolepsy type 1 (NT1). It is the first orexin receptor 2 agonist to reach patients, and the two largest pharmaceutical markets in Asia got it before the United States, where launch waits on a controlled substance scheduling decision.
For APAC Commercial Excellence and Marketing teams, the interest goes beyond sleep medicine. The launch shows how a first-in-class product moves through two very different systems at nearly the same time, and Japan's public price file gives an unusually clear look at how the government valued it. This article sets out the verified facts and the planning questions they raise.
What Takeda launched, and where
Approvals in three markets within weeks
Takeda's releases give the sequence:
- 22 July 2026: China's National Medical Products Administration (NMPA) approved ORZEYFUL for NT1 in adolescents aged 16 and older and in adults. Takeda China thanked the regulator for "enabling an accelerated review process".
- 5 August 2026: the US Food and Drug Administration (FDA) approved it for NT1 in adults, after Breakthrough Therapy designation and Priority Review.
- 24 August 2026: Japan's Ministry of Health, Labour and Welfare (MHLW) approved it for NT1 in adults. Takeda called this the third approval worldwide.
- 15 October 2026: Takeda announced availability in Japan and China.
Takeda says the medicine will launch in the US next month, after the Drug Enforcement Administration completes scheduling. The FDA's own release says the medicine will be lawful to market once that scheduling decision is issued.
Labels are not identical
The Chinese label covers adolescents aged 16 and older as well as adults. The US and Japanese labels cover adults only. For a regional team, that means patient numbers, the prescriber base and medical education needs differ by market from day one. In China, the label reaches into an age group where, according to Takeda, NT1 typically begins: the company says the disease usually develops between the ages of 10 and 20.
The adolescent label in China also widens the circle of people involved in a treatment decision. Parents, school-age patients and paediatric or adolescent sleep services may all play a part, and the questions they ask differ from those of working adults. Research in China should include clinicians who see younger patients, and should test how they weigh benefit, side effects and twice-daily dosing for a patient still in education. In Japan and the US, where the label covers adults only, that segment is not part of the launch, and regional materials should not imply otherwise.
How the orexin agonist for narcolepsy type 1 works
NT1 is a chronic, rare neurological disease caused by a loss of orexin, a brain messenger that regulates wakefulness, sleep and muscle tone. The FDA describes the result as a cluster of symptoms: excessive daytime sleepiness, cataplexy (sudden muscle weakness often triggered by strong emotion), sleep paralysis, hallucinations around sleep and disrupted night-time sleep. The FDA estimates that NT1 affects about 1 in 2,000 people in the United States.
ORZEYFUL is an oral tablet that selectively stimulates the orexin 2 receptor, the same receptor the body's own orexin would activate. The FDA calls it the first medicine approved for NT1 as a complete disorder and the first that directly targets the loss of orexin signalling. Until now, treatment has targeted individual symptoms.
The clinical evidence
The approvals rest on two global phase 3 studies, FirstLight and RadiantLight. Takeda reports that both were placebo-controlled over 12 weeks, ran in 19 countries, and completed enrolment within six months. FirstLight enrolled 168 participants and RadiantLight 105. The FDA describes them as randomised, double-blind studies enrolling 273 adults in total.
According to Takeda, results showed statistically significant improvements over placebo in wakefulness, sleepiness, cataplexy, disease severity and quality of life measures, with p-values below 0.001 across doses. The most common side effects reported were insomnia, urinary urgency, urinary frequency and excessive saliva. The FDA notes that the medicine should not be used with strong CYP3A inhibitors.
Dosing in Japan
Takeda's Japan product overview gives the usual adult dose as 1 mg twice daily, with the first dose on waking and the second three to five hours later. The dose can be raised to 2 mg twice daily only when it is well tolerated and efficacy is insufficient. Tablets come in 0.5 mg, 1 mg and 2 mg strengths.
Japan NHI price listing: reading the new drug file
In Japan, a new medicine is listed on the National Health Insurance (NHI) price list before it can be used under public insurance. The Central Social Insurance Medical Council (Chuikyo) approved the listing at its meeting on 7 October 2026, and the MHLW new drug list set the listing date as 14 October 2026. The file is public and shows how the price was built.
The listed prices
The MHLW file lists the price per tablet as:
- 0.5 mg: JPY 22,773.30
- 1 mg: JPY 22,792.50
- 2 mg: JPY 22,838.80
The three strengths are priced almost the same. For brand teams, that matters because a dose increase from 1 mg to 2 mg twice daily barely changes the cost per day. Payer and hospital conversations about cost will turn on the decision to treat, not on dose.
Cost accounting, because nothing comparable existed
The price was set by the cost accounting method, not by comparison with a similar medicine. The file explains why. No listed product has NT1 as its indication. Medicines listed for narcolepsy more broadly have all been on the list for more than ten years, so they are not suitable comparators. Products that act on orexin receptors are antagonists used for insomnia. The pricing body concluded there was no most-similar medicine.
Premiums and the addition coefficient
The file records three premiums:
- Usefulness premium (I) at 40%, because the medicine has a new mechanism of action and there had been no new-mechanism listing in this disease area for about 19 years and 7 months, and because it improved important secondary endpoints against placebo.
- Marketability premium (I) at 10%, because it is designated an orphan drug in Japan.
- Sakigake premium at 10%, because it was designated under the Sakigake review scheme. The rate was set at 10% because several other countries had approved it before Japan.
The addition coefficient is listed as 0, and the file shows identical prices before and after the premiums. In other words, the premiums were granted in principle but did not raise the listed price. There was no foreign average price adjustment, and the file states that no foreign price existed. It names China, in July 2026, as the first country of approval.
Price maintenance and cost-effectiveness review
The file states that the medicine qualifies for the system that maintains prices for innovative new drugs, mainly because of its orphan designation. It also lists the medicine as subject to cost-effectiveness evaluation, in category H2. That means the price is not final in the long term: an evaluation will follow, and the outcome may change it.
The company's own forecast
Japanese new drug files include the applicant's market forecast. Takeda forecast 423 patients and sales of JPY 7.04 billion in the tenth year, at peak. That is a small, concentrated patient group, which shapes how a launch should be resourced.
China: a different scale and a different route
Takeda's China approval release says narcolepsy affects an estimated 700,000 people in China, with NT1 making up about 75 to 80 percent of cases. These are company figures. Takeda also cites an average diagnostic delay of more than 10 years for narcolepsy, linked to limited awareness and complex symptoms.
Put next to Japan's forecast of 423 treated patients at peak, the contrast is stark, though the two numbers measure different things: one is a disease estimate, the other a treated-patient forecast. For a regional team, the point is that China's opportunity depends heavily on diagnosis. If many patients are undiagnosed or misdiagnosed, then sleep testing capacity and physician awareness will limit uptake more than the label will.
Takeda's releases do not say how ORZEYFUL is being reimbursed in China, and this article does not speculate. What is clear is that the China launch began with a broader label and a large estimated disease population, and that diagnosis is likely to be the main constraint.
Sleep centre account research: where adoption happens
A specialist, concentrated prescriber base
NT1 is diagnosed and managed mostly in sleep medicine centres and specialist neurology and psychiatry services. In Japan, a forecast of a few hundred treated patients at peak points to a small number of high-volume centres. In China, the leading centres are likely to sit in major teaching hospitals. Either way, the account list is short, and each account matters.
Account-level questions for APAC teams:
- Which centres diagnose the most NT1 patients, and what testing capacity do they have?
- Who decides on adding a new medicine to the hospital list in each centre?
- How do they manage patients today, and how many are already on several symptomatic treatments?
- How do they follow patients over time, and who else, such as general neurologists or psychiatrists, is involved?
Diagnosis as the bottleneck
Takeda cites a diagnostic delay of more than 10 years. Shortening that delay increases the number of patients a centre can treat. Research with referring physicians, not just sleep specialists, shows where patients get lost on the way to diagnosis, and what would make referrals faster.
Prescription-level questions for a first-in-class medicine
When a medicine is first in its class, prescribers have no habit to draw on. Prescription-level research should cover:
- Patient selection: which NT1 patients do sleep specialists treat first, by symptom burden, current treatment and age where the label allows?
- Switch or add: do they replace current treatments, add to them, or reduce them over time?
- Dosing: how often do they expect to increase to 2 mg twice daily, and what drives that choice?
- Side effects: how do they expect to manage insomnia and urinary symptoms, and how will they counsel patients?
- Outcome measures: which signs of success do they look for, and over what time frame?
Running the same core questions in Japan and China, with local adaptation, lets a regional team compare uptake drivers directly. For help designing those studies, see our overview of physician surveys in healthcare.
Why the US sequence matters to APAC teams
In its August release, Takeda said the DEA's controlled substance classification was expected within 90 days, and that ORZEYFUL would then be sold through a specialty pharmacy in the United States. That puts the US launch after the Asian launches, which is unusual for a global first-in-class medicine.
For APAC affiliates, this changes the usual flow of evidence. Japanese and Chinese sleep specialists will be among the first clinicians anywhere to prescribe the medicine outside clinical trials. Their early experience, on dose changes, side effect management and patient selection, will be watched by colleagues in other markets. Medical teams in the region have a chance to gather structured real-world feedback early, and commercial teams have a chance to learn which messages work before most of the world sees the product. That chance only pays off if the feedback is collected in a consistent way across centres and countries.
A franchise, not a single product
Takeda describes ORZEYFUL as the lead medicine in its orexin franchise. The company is also developing TAK-360 for NT1, narcolepsy type 2 and idiopathic hypersomnia, and another orexin agonist, TAK-495. For brand planning, that means the first launch builds relationships, data and diagnostic pathways that later products may use. Sleep centres that adopt the first medicine early are likely to be the same accounts that matter for later ones, especially if those later products reach patient groups beyond NT1.
That makes early account research more valuable. Knowing how each centre diagnoses, refers and follows patients is useful for this launch and for every later orexin product in the same accounts.
What APAC rare disease launch planning can learn
Regulatory speed does not equal patient access
Three approvals within roughly five weeks did not mean three launches at once. Japan needed NHI listing, China moved through its own system, and the US needed scheduling. The launch dates followed those local steps, not the approval dates.
A public price file is a free source of evidence
Japan's new drug file explains the pricing method, the premiums, the comparator decision and the company's forecast. Teams launching any new medicine in Japan should read the file for the closest analogue in their area before setting expectations.
Cost-effectiveness review is part of the plan
The H2 category means the evaluation outcome can affect the Japanese price after launch. Evidence on real-world outcomes, quality of life and resource use should be gathered from the start. Takeda notes that people with narcolepsy have about twice the rate of healthcare resource use of controls, which is the kind of claim that local data will need to support.
The same molecule, different labels
China's label includes patients from 16 years. Regional messaging, medical education and patient support need to follow each market's label exactly.
Frequently asked questions
What is ORZEYFUL (oveporexton)?
An oral orexin receptor 2 agonist from Takeda for narcolepsy type 1. The FDA calls it the first medicine to directly target the loss of orexin signalling that causes the disease.
Where is ORZEYFUL available?
Takeda announced availability in Japan and China on 15 October 2026. It says US launch will follow next month, after DEA scheduling.
Who can be treated?
In China, adolescents aged 16 and older and adults with NT1. In the US and Japan, adults with NT1.
What is the price in Japan?
The MHLW new drug list sets JPY 22,773.30 for 0.5 mg, JPY 22,792.50 for 1 mg and JPY 22,838.80 for 2 mg per tablet, listed from 14 October 2026.
How was the Japanese price set?
By the cost accounting method, because no suitable comparator existed. Premiums were granted, but the addition coefficient was 0, and the medicine is subject to cost-effectiveness evaluation (H2).
What should APAC teams research first?
The short list of sleep centres that diagnose most NT1 patients, the referral path to diagnosis, and how specialists will select and manage patients on a first-in-class medicine.
Plan your APAC launch research with BioNixus
BioNixus has run primary market research since 2012, with physician and account-level fieldwork across 48 countries, including Japan and China. We design studies around the specialist centres and prescribers who drive adoption of new medicines. See our work on healthcare market research in Japan and healthcare market research in China.
If you are preparing a first-in-class or rare disease launch in APAC, contact our team.
Based on public regulatory filings and company announcements. Nothing here is clinical guidance or a recommendation to prescribe.
Sources
All accessed 17 October 2026.
- Takeda, "Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China", 15 October 2026: https://www.takeda.com/newsroom/newsreleases/2026/oveporexton-launches-simultaneously-in-japan-and-china/
- Takeda China, "ORZEYFUL Approved in China for Narcolepsy Type 1", 22 July 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-china-narcolepsy/
- Takeda, "FDA Approves ORZEYFUL for Adults With Narcolepsy Type 1", 5 August 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-narcolepsy/
- US FDA, "FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms", 5 August 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
- Takeda, "ORZEYFUL Approved in Japan to Treat Narcolepsy Type 1", 24 August 2026: https://www.takeda.com/newsroom/newsreleases/2026/orzeyful-approved-japan-narcolepsy/
- MHLW, 新医薬品一覧表 (new drug list, listing 14 October 2026), Chuikyo 7 October 2026: https://www.mhlw.go.jp/content/10808000/001756860.pdf
- BioNixus, About page: https://www.bionixus.com/about